Literature DB >> 7512150

Establishment and application of SPA-co-operated ELISA for detection of anti-HCV-IgM.

F H Li1, L S Guo, Z Q Yu, Y K Wang, J Y Qi, X W Yuan, L J Hao.   

Abstract

A staphylococcus aureus protein A co-operated ELISA (SPA-ELISA) for the detection of anti-HCV-IgM has been established using HCV antigenic polypeptide, SPA-bearing germs and horseradish peroxidase labelled anti-human IgM. The specificity of SPA-ELISA has been confirmed by some substitution tests, blocking tests and destroying test with 2-mercaptoethanol. The results showed that the rate of anti-HCV-IgG in a group of patients with acute hepatitis and there were significant difference in anti-HCV-IgM was higher than that of anti-HCV-IgM detected rates between patients with acute hepatitis and those with chronic hepatitis (32.26%, P < 0.01). On the other hand, the positive rates of anti-HCV-IgM were 53.66% and 63.41% in transfusion associated hepatitis, 38.10% and 42.86% in sporadic hepatitis, 6.11% and 16.33% in people who have had active social activities, 40.00% and 10.00% in a group of blood donors respectively. Furthermore, taking into account the characteristics of HCV polypeptide used, its easiness of manipulation, and elimination of the interference of anti-HCV-IgG in sera, the new SPA-ELISA is believed to be of practical value in clinical and epidemiological studies of hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7512150     DOI: 10.1007/bf02888011

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  7 in total

1.  Antibodies against synthetic oligopeptides deduced from the putative core gene for the diagnosis of hepatitis virus infection.

Authors:  H Okamoto; F Tsuda; A Machida; E Munekata; Y Akahane; Y Sugai; K Mashiko; T Mitsui; T Tanaka; Y Miyakawa
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

2.  New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus.

Authors:  H J Alter
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

3.  IgM antibody to hepatitis C virus in acute and chronic hepatitis C.

Authors:  J A Quiroga; M L Campillo; I Catillo; J Bartolomé; J C Porres; V Carreño
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

4.  Immunoglobulin M antibody to hepatitis B core antigen in patients with chronic type B hepatitis.

Authors:  M Sjogren; J H Hoofnagle
Journal:  Gastroenterology       Date:  1985-08       Impact factor: 22.682

5.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

6.  Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C.

Authors:  S Brillanti; C Masci; P Ricci; M Miglioli; L Barbara
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425

7.  Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis.

Authors:  L J Jeffers; F Hasan; M De Medina; R Reddy; T Parker; M Silva; L Mendez; E R Schiff; M Manns; M Houghton
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.